CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 240 enrolled
Drug / intervention
paracetamol + caffeine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01686646
NCT01686646Phase 3Completed
CompareCT.gov

Effects of Two Doses of a Common Cold Treatment on Cognitive Function

GlaxoSmithKline·interventional·Posted Sep 18, 2012·Updated Dec 8, 2014

In Brief

A Phase 3 clinical trial evaluating paracetamol + caffeine and paracetamol for Common Cold. Completed, enrolled 240 participants across 1 site.

Detailed Summary

This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartNov 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.8 years ago

Interventions

paracetamol + caffeinedrug

paracetamol with caffeine

paracetamoldrug

paracetamol